Abstract
Many pharmacodynamic (PD) models of cellular response assume a single and time invariant lifespan of all cells, despite the existence of a true underlying distribution of cellular lifespans and known changes in the lifespan distributions with time. To account for these features of cellular populations, a time variant cellular lifespan distribution PD model was formulated and theoretical aspects of modeling cellular populations presented. The model extends prior work assuming time variant “point distributions” of cellular lifespans (Freise et al. J Pharmacokinet Pharmacodyn 34:519–547, 2007) and models assuming a time invariant lifespan distribution (Krzyzanski et al. J Pharmacokinet Pharmacodyn 33:125–166, 2006). The formulated time variant lifespan distribution model was fitted to endogenous plasma erythropoietin (EPO), reticulocyte, and red blood cell (RBC) concentrations in sheep phlebotomized on two occasions, 8 days apart. The time variant circulating reticulocyte lifespan was modeled as a truncated and scaled Weibull distribution, with the location parameter of the distribution non-parametrically represented by an end constrained quadratic spline function. The formulated time variant lifespan distribution model was compared to the identical time invariant distribution, time variant “point distribution” and time invariant “point distribution” cellular lifespan models. Parameters of the time variant lifespan distribution model were well estimated with low standard errors. The mean circulating reticulocyte lifespan was estimated at 0.304 days, which rapidly increased over 3-fold following the first phlebotomy to a maximum of 1.03 days (P = 0.009). On average, the percentage of erythrocytes being released as reticulocytes maximally increased an estimated two-fold following the phlebotomies. The primary features of immature RBC physiology were captured by the model and gave results consistent with other estimates in sheep and humans. The comparison of the four lifespan models gave similar parameter estimates of the stimulation function and fits to the RBC data. However, the time invariant models fit the reticulocyte data poorly, while the time variant “point distribution” cellular lifespan model gave physiologically unrealistic estimates of the changes in the circulating reticulocyte lifespan under stress erythropoiesis. Thus the underlying physiology must be considered when selecting the most appropriate cellular lifespan model and not just the goodness-of-fit criteria. The proposed PD model and the numerical implementation allows for a flexible framework to incorporate time variant lifespan distributions when modeling populations of cells whose production or stimulation depends on endogenous growth factors and/or exogenous drugs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dornhorst AC (1951) The interpretation of red cell survival curves. Blood 6: 1284–1292
Callender ST, Powell EO, Witts LJ (1945) The life span of the red cell in man. J Pathol Bacteriol 57: 129
Brown GM, Hayward OC, Powell EO, Witts LJ (1944) The destruction of transfused erythrocytes in anemia. J Pathol Bacteriol 56: 81
Landaw SA (1988) Factors that accelerate or retard red blood cell senescence. Blood Cells 14: 47–67
Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (2005) Hematology: basic principles and applications, 4th edn. Elsevier Inc., United States of America
Brugnara C (2000) Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 37: 93–130
Hillman RS, Ault KA, Rinder HM (2005) Hematology in clinical practice, 4th edn. McGraw-Hill Companies Inc., United States of America
Harvey JW (2001) Atlas of veterinary hematology blood and bone marrow of domestic animals. W.B. Saunders Company, Philadelphia
Brugnara C (1998) Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 28: 1–11
Jandl JH (1996) Blood: textbook of hematology, 2nd edn. Little, Brown and Company, United States of America
Houwen B (1992) Reticulocyte maturation. Blood Cells 18: 167–186
Jain NC (1993) Essential of veterinary hematology. Lea & Febiger, Philadelphia
Friberg LE, Freijs A, Sandstrom M, Karlsson MO (2000) Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295: 734–740
Veng-Pedersen P, Chapel S, Schmidt RL, Al-Huniti NH, Cook RT, Widness JA (2002) An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia. Pharm Res 19: 1630–1635
Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA (2000) A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther 295: 346–351
Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26: 295–306
Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ (2003) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 306: 324–331
Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44: 991–1002
Krzyzanski W, Ramakrishnan R, Jusko WJ (1999) Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 27: 467–489
Krzyzanski W, Perez-Ruixo JJ (2007) An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res 24: 758–772
Uehlinger DE, Gotch FA, Sheiner LB (1992) A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51: 76–89
Krzyzanski W, Woo S, Jusko WJ (2006) Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J Pharmacokinet Pharmacodyn 33: 125–166
Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P (2007) Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep. J Pharmacokinet Pharmacodyn 34: 519–547
Kalbfeisch JD, Prentice RL (2002) The statistical analysis of failure time data, 2nd edn. Wiley, Hoboken, NJ
Grimes JM, Buss LA, Brace RA (1987) Blood volume restitution after hemorrhage in adult sheep. Am J Physiol 253: R541–R544
Widness JA, Veng-Pedersen P, Modi NB, Schmidt RL, Chestnut DH (1992) Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J Pharmacol Exp Therapeut 261: 977–984
Veng-Pedersen P, Mandema JW, Danhof M (1991) A system approach to pharmacodynamics. III: an algorithm and computer program, COLAPS, for pharmacodynamic modeling. J Pharm Sci 80: 488–495
Hutchinson MF, deHoog FR (1985) Smoothing noise data with spline functions. Numer Math 47: 99–106
Mock DM, Lankford GL, Burmeister LF, Strauss RG (1997) Circulating red cell volume and red cell survival can be accurately determined in sheep using the [14C]cyanate label. Pediatr Res 41: 916–921
Akaike H (1974) Automatic control: a new look at the statistical model identification. IEEE Trans 19: 716–723
Veng-Pedersen P (1977) Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5: 513–531
Piessens R, deDoncker-Kapenga E, Uberhuber CW, Kahaner DK (1983) QUADPACK. Springer-Verlag, New York
Holm S (1979) A simple sequentially rejective multiple test procedure.. Scand J Stat 6: 65–70
Torrington KG, McNeil JS, Phillips YY, Ripple GR (1989) Blood volume determinations in sheep before and after splenectomy. Lab Anim Sci 39: 598–602
Hillman RS (1969) Characteristics of marrow production and reticulocyte maturation in normal man in response to anemia. J Clin Invest 48: 443–453
Shimada A (1975) The maturation of reticulocytes. II. Life-span of red cells originating from stress reticulocytes. Acta Med Okayama 29: 283–289
Stohlman F Jr (1961) Humoral regulation of erythropoiesis. VII. Shortened survival of erythrocytes produced by erythropoietine or severe anemia. Proc Soc Exp Biol Med 107: 884–887
Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P (2005) Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis. J Pharmacokinet Pharmacodyn 32: 359–376
Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W (2000) Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95: 2514–2522
Paulus JM (1971) Platelet kinetics: radioisotopic, cytological, mathematical, and clinical aspects. North-Holland Publishing Co., Amsterdam
Wiczling P, Krzyzanski W (2007) Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. Cytometry A 71: 460–467
Author information
Authors and Affiliations
Corresponding author
Additional information
Prepared for submission to Journal of Pharmacokinetics and Pharmacodynamics.
Rights and permissions
About this article
Cite this article
Freise, K.J., Widness, J.A., Schmidt, R.L. et al. Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep. J Pharmacokinet Pharmacodyn 35, 285–323 (2008). https://doi.org/10.1007/s10928-008-9089-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-008-9089-1